Systemic treatment, including monoclonal antibodies against tumor-associated targets, has increased the median survival of patients with metastatic colorectal cancer over 100% in the past few years. The prolonged life-span of these patients has led to the development of new and unusual complications that were typically not seen in the era of 5-fluorouracil and leucovorin. A multidisciplinary approach is now more crucial than ever. In this report, we will discuss a patient who presented with a metastatic lesion nearly obstructing the small bowel three years following the diagnosis of metastatic colon cancer.
|Original language||English (US)|
|Issue number||SPEC. ISS. 2|
|State||Published - May 1 2009|
- Multi-modality therapy
ASJC Scopus subject areas
- Pharmacology (medical)
- Cancer Research